Login

Concord Biotech Ltd.

₹1596.55

Overview Charts Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Corp. Action Documents
Consolidated
Standalone

Concord Biotech Ltd.

₹1596.55

₹1596.55

14.5 (0.92%) - 8 Apr 2025 04:26 PM

About Company

Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including regulated markets, such as the United States, Europe and Japan and India. It commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. In 2016, it launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.

Market Cap. ₹16,551 Cr.
52 Week - High/Low ₹2,664/1,327
P/E Ratio 50.43
P/B Ratio 10.85
Enterprise Value ₹16,536 Cr.
ROE % 21.63
RSI Value 39.24
EMA 50 1786.35
EMA 200 1823.34
Net Profit 305 Cr.
Net Profit 3year growth 29.51 Cr.
Net Profit 3 year (back) 235 Cr.
Debt to Equity 0.0 %
EPS Growth TTM 9.0 %
Current Ratio 6.3 %
100 Day SMA 1,974 Rs.
200 Day SMA 1,881 Rs.
21 Day SMA 1,667 Rs.
50 Day SMA 1,820 Rs.
Book Value 146 Rs.
EV/EBITDA Ratio 33
QoQ EPS Growth -25 %
QoQ Operating Profit Growth -28 %
QoQ Sales Growth -21 %
Sales Latest Quarter 244 Cr.
YoY Sales Growth 1 %
Market Cap. ₹16,551 Cr.
52 Week - High/Low ₹2,664/1,327
P/E Ratio 50.72
P/B Ratio 10.84
Enterprise Value ₹16,536 Cr.
ROE % 21.88
RSI Value 39.24
EMA 50 1786.35
EMA 200 1823.34
Net Profit 308 Cr.
Net Profit 3year growth 1.93 Cr.
Net Profit 3 year (back) 235 Cr.
Debt to Equity 0.0 %
EPS Growth TTM 7.15 %
Current Ratio 6.3 %
100 Day SMA 1,974 Rs.
200 Day SMA 1,881 Rs.
21 Day SMA 1,667 Rs.
50 Day SMA 1,820 Rs.
Book Value 146 Rs.
EV/EBITDA Ratio 33
QoQ EPS Growth -21 %
QoQ Operating Profit Growth -25 %
QoQ Sales Growth -21 %
Sales Latest Quarter 244 Cr.
YoY Sales Growth 1 %
Add Parameters

Growth

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Terms | Privacy | Contact Us
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.